- Home
- EML vs TLSI Comparison
EML vs TLSI Comparison
Compare EML & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | TLSI |
|---|---|---|
| Founded | 1858 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EML | TLSI |
|---|---|---|
| Price | $19.87 | $7.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 12.1K | ★ 258.1K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $40,207,000.00 |
| Revenue This Year | $1.56 | $55.06 |
| Revenue Next Year | $7.00 | $46.04 |
| P/E Ratio | $19.56 | ★ N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $18.49 | $3.42 |
| 52 Week High | $30.03 | $7.70 |
Technical Indicators
Market Signals| Indicator | EML | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 69.62 |
| Support Level | $19.28 | $6.96 |
| Resistance Level | $20.86 | $7.53 |
| Average True Range (ATR) | 0.63 | 0.51 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 67.16 | 84.86 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.